

DAFTAR PUSTAKA

- Alere Technologies AS. 2017. Lymphoprep™. Axis Shiled. Norwegia.
- American Cancer Society. 2014. Cancer Facts and Figures, hlm. 1-6 American Cancer Society. Atlanta GA, USA
- American Type Culture Collection. 2014. ATCC® ANIMAL CELL CULTURE GUIDE:tips and techniques for continuous cell lines. Manassas, USA, hlm 18-20
- Anderson S, Thouand G and Marks R 2014. Bioluminescence: Fundamentals and Applications in Biotechnology–Volume 2: Advances in Biochemical Engineering/Biotechnology. Hlm.145-189.
- Bernal S. 1998. Drug Resistance in Oncology: Resistance in Cytotoxic Drugs in Acute Leukemia. hlm. 250-269. CRC Press. USA
- Blair HA. 2018. Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia. Drugs, vol.78, ed.18, hlm.1903–1910.
- Behl C dan Ziegler C. 2014. Cell Aging: Molecular Mechanisms and Implications for Disease., hlm.9-19. Springer Briefs in Molecular Medicine
- Blom K, Nygren P, Larsson R, Andersson CR. 2017. Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis. SLAS TECHNOLOGY: Translating Life Sciences Innovation, vol 22, ed (3), hlm.306–314.
- Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, et al. 2017. Treated secondary Leukemia Mieloid Akut: a distinct high-risk subset of AML with adverse prognosis. Blood Advances Journal., vol.1, ed.17, hlm.1312-1323.
- Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. 2014. Leukemia, vol. 28, ed. 8, hlm. 1657-65.
- Bray LJ, Binner M, Körner Y, von Bonin M, Bornhäuser M, Werner C. 2017. A three-dimensional *ex vivo* tri-culture model mimics cell-cell interactions between acute myeloid leukemia and the vascular niche. Haematologica, Vol.102, ed.7, hlm.1215-1226
- Canadian Institutes of Health Research. 2019. Daunorubicin. Diperbaharui 3 Januari 2019. Terdapat di <https://www.drugbank.ca/drugs/DB00694>. Diakses pada tanggal 7 Januari 2019.hlm 1-27.
- Cassier PA, Castets M, Belhabri A, Vey N. 2017. Targeting apoptosis in acute myeloid leukaemia. British Journal of Cancer, vol 117, hlm 1089-1098
- Cayman chemicals. 2018. Daunorubicin. Cayman Chemicals Industries. hlm. 1-2

- Deng R, Fan FY, Yi H, Fu L, Zeng Y, Wang Y, Miao XY, Shuai YR, He GC, Su Y. 2017. Cytotoxic T Lymphocytes Promote Cytarabine-Induced Leukemia Mieloid Akut Cell Apoptosis via Inhibiting Bcl-2 Expression. *Experimental And Therapeutic Medicine*, vol.14, hlm.1081-1085.
- Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. 2017. *Blood Journal*, vol.129, ed.4, hlm.:424-447.
- Drugbank. 2016. Azacitidine. Didapatkan di <https://www.drugbank.ca/drugs/DB00928>. Diakses pada 16 Januari 2019.
- Emadi A. 2015. Exploiting AML vulnerability: glutamine dependency. *Blood Journal*, vol.126, hlm.1269-1270.
- Ersvaer E, Brenner AK, Vetås K, Reikvam H, Bruserud O. 2015. Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid. *BMC Pharmacology Toxicology*, vol. 16, ed.12, hlm.1-16
- Estey EH. 2018. Acute myeloid leukemia: 2019 update on risk-stratification and management. *Am J Hematol*. 2018 Oct;93(10):1267-1291.
- Fakih ROE, Champlin R, Oran B. 2015. 5-Azacitidine for treating acute myelogenous leukemia. *Expert Opinion on Orphan Drugs*, vol.3, ed.10, hlm.1197-1207
- Fateen MA, El Demerdash DM., Zayed RA., Mattar MM. 2019. Role of physical function in predicting short-term treatment outcome in Egyptian acute myeloid leukemia patients: a single center experience. *Hematology, Transfusion and Cell Therapy*, vol.41, ed.1, hlm.17-24.
- Fitriah M. 2017. Karya Akhir: Perbandingan Indeks Proliferasi Limfosit Pasca Stimulasi Antigen ESAT-6, CFP-10 dan Fusi ESAT-6-CFP-10, hlm. 31,32,44. Program Pendidikan Dokter Spesialis Patologi Klinik Fakultas Kedokteran Universitas Airlangga Surabaya Indonesia.
- Freshney RI. 2016. *Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications*, hlm.1-128. 173-175, 289-300. Wiley-Blackwell. USA
- Gang AO, Frøsig TM, Brimnes MK, et al. 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. *Blood Cancer J*. 2014, vol.4, ed.3, hlm. e197-e211.
- Halim NAA, Wong GC, Aloysius HYL, Hwang WYK, Linn YC, Lao Z. 2016. High Dose Cytarabine Is Superior to Intermediate Dose Cytarabine As Post-Remission Therapy for Younger Patients with Favorable Risk Acute Myeloid Leukemia. *Blood*, vol.128, hlm. 4032
- Hardie DG. Regulation of AMP-activated protein kinase by natural and synthetic activators. 2016. *Acta Pharmaceutica Sinica B*, vol 6, ed.1, hlm 1-19.

- Heasman SA, Zaitseva L, Bowles KM, Rushworth SA, MacEwan DJ. 2011. Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. *Oncotarget*, September, Vol.2, No.9, hlm.658-668
- Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y. (2010) A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines. *PLoS ONE* , vol.5, ed.2, artikel e9001, hlm.1-11.
- Hull R. 2014. *Plant Virology 5th Edition* . Chapter Assay, Detection, and Diagnosis of Plant Viruses, hlm. 755-808. Elsevier. USA.
- Huls G. 2015. Azacitidine in AML: a treatment option?. *Blood*, vol. 126:283-284
- Kadia TM, Ravandi F, Cortes J, Kantarjian H. 2015. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review. *JAMA Oncol*, vol.1, ed.6, hlm.820–828.
- Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, et al. 2016. *TP53* mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. *Cancer*, vol.122:, hlm.3484-3491.
- Kim JH, Lee CS, Cheong HS, Koh Y, Kwang SA, Kim HL, Shin HD et al. 2016. *SLC29A1 (ENT1)* polymorphisms and outcome of complete remission in acute myeloid leukemia. *Cancer Chemotherapy Pharmacol*, vol. 78, ed.3, hlm.533–540
- Klobuch S, Steinberg T, Bruni E, Mirbeth C, Heilmeyer B, Ghibelli L, Thomas S. 2018. Biomodulatory Treatment With Azacitidine, All-*trans*Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis. *Frontiers in pharmacology*, vol.9, article1380, hlm. 1-11.
- Ko YC, Hu CY, Liu ZH, Tien HF, Ou DL, Chien HF, Lin LI. Cytarabine-Resistant *FLT3*-ITD Leukemia Cells are Associated with *TP53* Mutation and Multiple Pathway Alterations-Possible Therapeutic Efficacy of Cabozantinib. *Int J Mol Sci*. 2019 Mar 11;20(5):1230.
- Koyanagi M, Kawakabe S, Arimura Y. 2016. A comparative study of colorimetric cell proliferation assays in immune cells. *Cytotechnology*, vol 68, hlm.1489–1498.
- Laille E, Shi T, Garcia-Manero G, Cogle CR, Gore SD, Hetzer J, et al. 2015. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. *PLoS ONE* 10(8): e0135520, hlm. 1-19.
- Liesveld JL dan Lichtman MA. 2016. Part X: Malignant Myeloid Disease, hlm. 1373-1415. In K Kaushansky (edt). *William's Hematology 9th ed*. McGraw-Hill Education. USA

- Li W, Gong X, Sun M, Zhao X, Gong B, et al. 2014. High-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis. *PLoS ONE* 9(10): e110153. doi:10.1371/journal.pone.0110153
- Li Z, Guo JR, Chen QQ, Wang CY, Zhang WJ, Yao MC, Zhang W. 2017. Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Leukemia HL-60 Cells. *Molecules*, vol. 22, No.499, hlm.1-10
- Lü L, Zhang L, Wai MSM, Yew DTW, Xu J. 2013. Exocytosis of MTT formazan could exacerbate cell injury. *Toxicology In Vitro Journal*, Vol 26, ed.4, hlm. 636-44.
- Ma'at S. 2011. Teknik dasar: Kultur sel. Surabaya. Pusat Penerbitan dan Percetakan Unair (AUP). ISBN, 6028967521,9786028967525, hlm 1-25, 79-87, 127-138.
- _____. 2013. Imunologi Laboratorium: Uji Fungsi Sel Imunokompeten. Surabaya-Indonesia. Global Persada Press, hlm 81-86, 123-126.
- Maegawa S, Gough SM, Watanabe-Okochi N. 2014. Age-related epigenetic drift in the pathogenesis of MDS and AML. *Genome Res* 24:580–591.
- Macanas-Pirard P, Broekhuizen R, González A, Oyanadel C, Ernst D, García P, Montecinos VP, et al. Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome. *Oncotarget*. 2017 Apr 4;8(14):23073-23086.
- Momparler RL. 2013. Optimization of cytarabine (ARA-C) therapy for Leukemia Mieloid Akut. *Experimental Hematology & Oncology*, vol.2, ed.20, hlm. 1-5
- Murphy T dan Yee KWL. 2017. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia, *Expert Opinion on Pharmacotherapy*, 18:16, hlm 1765-1780
- National Center for Biotechnology Information. 2015. PubChem Compound Database; CID=9444: Azacitidine. Didapatkan di <https://pubchem.ncbi.nlm.nih.gov/compound/9444>. Diakses tanggal 17 Januari 2019
- National Cancer Institute. 2019. Surveillance Epidemiology and End Results Program: Cancer Stat Facts-Leukemia-Acute Myeloid Leukemia Didapatkan di <https://seer.cancer.gov/statfacts/html/amyl.html>. Diakses tanggal 17 Juni 2019.
- Nomdedeu M, Lara-Castillo MC, Etxabe A, Cornet-Masana JM, Pratcorona M, Díaz-Beyá, M, Risueño RM. (2015). Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma. *Cancer cell international*, 15, 122. doi:10.1186/s12935-015-0272-3

- O'Donnell MR, TalAMLn MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, et al. Leukemia Mieloid Akut, Version 3.2017. Journal of National Comprehensive Cancer Network (NCCN) 2017, vol.15, ed.7, hlm 926–957.
- Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Sz wajda A, Almusa H, et al. 2013. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. *Cancer discovery*, vol.3, ed. 12, hlm.1416-29
- Pleyer L, Döhn r H, Dombret H, Seymour JF, Schuh AC, Beach CL, Swern AS, et al. 2017. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group *Int. J. Mol. Sci*, vol.18, No.415; hlm.1-18
- Pleyer L dan Greil R. Digging deep into “dirty” drugs – modulation of the methylation machinery. *Drug Metab Rev.* 2015 Apr 3; 47(2): 252–279.
- Prekert M. 2011. On mechanisms of drug resistance in acute myeloid leukemia. *Orebro Studies in Medicine*, vol.45, hlm.1-88.
- Rantam FA, Ferdiansyah, Purwati. 2014. *Stem Cell: Mesenchymal*, Hematopoetik dan Model Aplikasi. Surabaya. Airlangga University Press, hlm.1-20, 89-91.
- Riss TL, Moravec RA, Niles AL, DuellAMLn S, Benink, HA, Worzella TJ, Minor L. 2016. Cell Viability Assays. In GS Sittampalam, (ed.). *Assay Guidance manual*. Eli Lilly & Company and the National Center for Advancing Translational Science, Bethesda MD, USA, hlm. 357-388.
- Romanski A dan Bug G. 2016. Establishment and Characterization of Long-Term Cultures Derived from Primary Acute Myeloid Leukemia Cells for HDAC Inhibitor Research. Hlm.127–148. In Oliver H. Krämer (ed.), *HDAC/HAT Function Assessment and Inhibitor Development: Methods and Protocols*, Methods in Molecular Biology, vol. 1510. Springer Science+Business Media New York 2017
- Sargent JM, Taylor CG. 1989. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia. *British Journal of Cancer*, vol.60, hlm. 206-210
- Schwarer AP, Butler J, Jackson K, Beligaswatte A, Martin L, Kennedy G, Daniela Z, et al. Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML. *Hemasphere*, 2018; vol.2, ed 1, hlm. 1-11.
- Seiter K. 2017. Acute Myeloid Leukemia (AML): Practice Essentials, Pathophysiology, Etiology. Terdapat di <https://emedicine.medscape.com/article/197802-overview#showall> 1/5.

Diakses pada tanggal Nov 19th 2018.

- Septisetyani EP, Ningrum RA, Romadhani Y, Wisnuwardhani PH, Santoso A. 2014. Optimization Of Sodium Dodecyl Sulphate As A Formazan Solvent And Comparison Of 3-(4,5-Dimethylthiazo-2-Yl)-2,5-Diphenyltetrazolium Bromide (Mtt) Assay With Wst-1 Assay In Mcf-7 Cells. *Indonesian J. Pharm.* Vol. 25, No. 4, hlm: 245 – 254
- Shepshelovich D, Edel Y, Goldvaser H, Dujovny T, Wolach O, Raanani P. 2015. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. *Brittish Journal of Clinical Pharmacology*, vol.79, ed.4, hlm. 685-91.
- Short J, Rytting N E, Cortes M, Jorge E. 2018. Acute myeloid leukaemia. *The Lancet Journal*, vol.392, hlm.1-14. 10.1016/S0140-6736(18)31041-9.
- Sigma Aldrich. 2016. Thiazolyl Blue Tetrazolium Bromide. Sigma Aldrich Merck . Hlm. 1-2
- Sigma-Merck. 2016. Isolation of mononuclear cells:Methodology and applications. GE Healthcare Sweden.Hlm.1-16
- Sripayap P, Nagai T, Uesawa M, Kobayashi H, Tsukahara T, Ohmine K¹, Muroi K⁴, et al.Mechanisms of resistance to azacitidine in human leukemia cell lines. *Exp Hematol.* 2014 Apr;42(4):294-306.e2.
- Specchia G, Mestice A, Coppi MR, Pastore D, Carluccio P, Ricco A, Attolico M, et al(1998) Correlation of in Vitro Drug Sensitivity with Clinical Outcome in Adult AML. In: Hiddemann W. et al. (eds) *Acute Leukemias VII. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion*, vol 39. Springer, Berlin, Heidelberg, Jerman.
- Swords RT, Azzam D, Al-Ali H, Lohse I, Volmar CH, Watts JM, Perez A, et al. 2018. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. *Leuk Res.*;64:34-41. doi: 10.1016/j.leukres.2017.11.008. Epub 2017 Nov 11. PubMed PMID: 29175379; PubMed Central PMCID: PMC5756519.
- Thomas TT dan Hernaningsih Y. 2017. Pola Hasil Pemeriksaan Immunophenotyping Kasus Leukemia Akut Pada Pasien Dewasa Di RSUD Dr. Soetomo dan RS Universitas Airlangga Januari 2012 – Juni 2017. Terdapat di [Http://Repository.Unair.Ac.Id/ Id/Eprint/68439](http://Repository.Unair.Ac.Id/Id/Eprint/68439). Diakses pada tanggal November 20th 2018.
- Rifai N, Horvath AR, Wittwer CT. 2018. Chapter 3: Preanalytical Variation. In *Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics 8th ed*, hlm.42-44
- Tawfik B, Pardee TS, Isom S, Sliesoraitis S, Winter A, Lawrence J, Powell BL, et al. 2016. Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). *Journal of Geriatric Oncology*, vol.7, ed.1, hlm.:24-31.

- Tombak A, Uçar MA, Akdeniz A, Tiftik EN, Şahin DG, Akay OM, Yıldırım M, et al. 2016. The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study Turkish Journal of Hematology, vol.33, hlm.273-280
- Tyleckova, J., Hrabakova, R., Mairychova, K., Halada, P., Radova, L., Dzubak, P., Kovarova, H. 2012. Cancer cell response to anthracyclines effects: mysteries of the hidden proteins associated with these drugs. *International journal of molecular sciences*, vol.13, no.12, hlm.15536–15564.
- Union For International Cancer Control. 2014. ACUTE MYELOGENOUS LEUKEMIA AND ACUTE PROMYELOCYTIC LEUKEMIA. Terdapat di [www.who.int /Selection_Medicines/Committees/Expert/20/.../AML_APL.Pdf](http://www.who.int/selection_medicines/committees/expert/20/aml_apl.pdf). Diakses pada tanggal November 21st 2018.
- University of Utah. Table of contents for issues of Applied Statistics. Diperbaharui Sep 26th 2018 . Terdapat di <http://ftp.math.utah.edu/pub/tex/bib/toc/as1970.html>. Diakses pada tanggal 20 November 2018.
- Wagner A., Hempel G., Gumbinger H.G., Jürgens H., Boos J. 1999. Pharmacokinetics of Anticancer Drugs In Vitro. Hlm. 397-408. In: Kaspers G.J.L., Pieters R., Veerman A.J.P. (eds) Drug Resistance in Leukemia and Lymphoma III. Advances in Experimental Medicine and Biology, vol 457. Springer, Boston, MA
- Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, et al. 2015. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. *Leukemia*, vol.29, ed.2, hlm.312-320.
- Wass M, Hitz F, Schaffrath J, MüllerTidow C, Müller LP. 2016. Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia. PLoS ONE, vol.11, ed.10, artikel e0164587, hlm.:1-11.
- Willemze R, Suci S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, et al. 2014. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. Journal of Clinical Oncology, Vol. 32, ed.3, hlm.219-28.
- Yang and Wang. 2018. Precision therapy for acute myeloid leukemia. *Journal of Hematology & Oncology*, vol. 11, ed.3, hlm. 1-11
- Yao T dan Asayama Y. 2017. Animal-cell culture media: History, characteristics, and current issues. Wiley. *Reproductive Medicine Biology*, vol 16, hlm 99-117.
- Yeung CCS dan Radich J. 2017. Predicting Chemotherapy Resistance in AML. *Current Hematology Malignancy Report*, vol.12, ed. 6, hlm 530-536.

Yin F dan Malkovska V. 2013. Chapter 11: Acute Myeloid Leukemia hlm. 137-157. In Rodgers dan Young The Bethesda Handbook of Clinical Hematology 3rd ed. Lippincott Williams & Wilkins. USA.